165 related articles for article (PubMed ID: 37293170)
1. CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade glioma.
Xiao F; Sun G; Zhu H; Guo Y; Xu F; Hu G; Huang K; Guo H
Am J Cancer Res; 2023; 13(5):2135-2154. PubMed ID: 37293170
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis based on vesicle trafficking-related genes identifying CNIH4 as a novel therapeutic target for glioma.
Fang Z; Kong F; Zeng J; Zhang Z; Wang Y; Wang Y; Duan J; Chen L; Wang J; Liu F
Cancer Med; 2023 Jun; 12(11):12943-12959. PubMed ID: 37062068
[TBL] [Abstract][Full Text] [Related]
3. MGME1 associates with poor prognosis and is vital for cell proliferation in lower-grade glioma.
Xiao F; Zeng J; Wang H; Zhu H; Guo Y; Zhang Z; Xiao Y; Hu G; Huang K; Yang Q; Guo H
Aging (Albany NY); 2023 May; 15(9):3690-3714. PubMed ID: 37166417
[TBL] [Abstract][Full Text] [Related]
4. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.
Xiao F; Jie X; Zhou X; Guo Y; Sun GF; Lin L; Hu GW; Huang K; Guo H
Biosci Rep; 2023 May; 43(5):. PubMed ID: 37083601
[TBL] [Abstract][Full Text] [Related]
5. MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.
Xiao F; Long Z; Guo Y; Zhu H; Zhang Z; Xiao Y; Hu G; Yang Q; Huang K; Guo H
Aging (Albany NY); 2023 Jun; 15(12):5713-5733. PubMed ID: 37390121
[TBL] [Abstract][Full Text] [Related]
6. Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma.
Liu H; Li Y
Cancer Biomark; 2022; 35(4):439-450. PubMed ID: 36404537
[TBL] [Abstract][Full Text] [Related]
7. CIA-II is associated with lower-grade glioma survival and cell proliferation.
Xiao F; Zhu H; Guo Y; Zhang Z; Sun G; Xiao Y; Hu G; Huang K; Guo H
CNS Neurosci Ther; 2024 Feb; 30(2):e14340. PubMed ID: 37452510
[TBL] [Abstract][Full Text] [Related]
8. Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification.
Aili Y; Maimaitiming N; Maimaiti A; Liu W; Qin H; Ji W; Mahemuti Y; Wang Y; Wang Z
J Oncol; 2022; 2022():2621969. PubMed ID: 36504559
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer.
Wang J; Wang S; Wang J; Huang J; Lu H; Pan B; Pan H; Song Y; Deng Q; Jin X; Shi G
Cancer Med; 2023 Dec; 12(24):22381-22394. PubMed ID: 38087815
[TBL] [Abstract][Full Text] [Related]
10. DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma.
Xiao F; Zhu H; Guo Y; Zhang Z; Sun G; Huang K; Guo H; Hu G
Aging (Albany NY); 2023 Jun; 15(12):5673-5697. PubMed ID: 37387540
[TBL] [Abstract][Full Text] [Related]
11. NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma.
Ren W; Yang S; Chen X; Guo J; Zhao H; Yang R; Nie Z; Ding L; Zhang L
Front Oncol; 2022; 12():918606. PubMed ID: 35898895
[TBL] [Abstract][Full Text] [Related]
12. CNIH4 governs cervical cancer progression through reducing ferroptosis.
Yang JY; Ke D; Li Y; Shi J; Wan SM; Wang AJ; Zhao MN; Gao H
Chem Biol Interact; 2023 Oct; 384():110712. PubMed ID: 37716418
[TBL] [Abstract][Full Text] [Related]
13. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
15. Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma.
Wang G; Cen Y; Wang C; Xiang W; Li S; Ming Y; Chen L; Zhou J
Transl Cancer Res; 2022 Jun; 11(6):1552-1564. PubMed ID: 35836526
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
17. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
18. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
19. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
Front Oncol; 2021; 11():654350. PubMed ID: 33954112
[TBL] [Abstract][Full Text] [Related]
20. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
